Janani Rangaswami, MD, director of the cardiorenal program at George Washington University in Washington, D.C., said the new study provides doctors the means to help patients understand the value of statins versus supplements.
"These data are so important and will really help you and I, and others, sit and show this to our patients and say, 'Here's what you're getting for your money,'" Rangaswami said. "The benefit even with low-dose rosuvastatin is way more impressive than all these other supplements and placebo."
